Francis K. L. Chan, MD, of the Chinese University of Hong Kong, and colleagues conducted an industry-independent, double-blind, double-dummy randomized trial in a Hong Kong hospital.
Researchers enrolled 514 patients, assigning patients randomly to receive either celecoxib twice per day; esomeprazole once per day; or naproxen twice per day with esomeprazole once per day. All patients received aspirin once per day. Researchers measured recurrent upper GI bleeding within 18 months as the primary endpoint.
Here’s what they found.
1. Of the 514 patients, recurrent bleeding occurred in 14 celecoxib patients and 31 naproxen patients.
2. Cumulative recurrent bleeding incidence rate was 5.6 percent in naproxen patients
3. Excluding patients who reached the study endpoints, 21 celecoxib patients and 17 naproxen patients had adverse events leading to treatment discontinuation.
4. No treatment-related deaths occurred.
Researchers concluded, “In patients at high risk of both cardiovascular and gastrointestinal events who require concomitant aspirin and NSAID, celecoxib plus proton-pump inhibitor is the preferred treatment to reduce the risk of recurrent upper gastrointestinal bleeding. Naproxen should be avoided despite its perceived cardiovascular safety.”
More articles on gastroenterology:
Bowel cancer mortality rates drop 30% — 4 study insights
GI leader to know: Dr. Louis Leite of Pennsylvania Gastroenterology
2 new GI-driven ASCs & facilities — March 2017
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
